Publication: A Randomized Double-Blind Placebo-Controlled Trial of Combined Escitalopram and Memantine for Older Adults With Major Depression and Subjective Memory Complaints
Issued Date
2019-01-01
Resource Type
ISSN
15457214
10647481
10647481
Other identifier(s)
2-s2.0-85071925957
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
American Journal of Geriatric Psychiatry. (2019)
Suggested Citation
Helen Lavretsky, Kelsey T. Laird, Beatrix Krause-Sorio, Brandon F. Heimberg, Jillian Yeargin, Adrienne Grzenda, Pauline Wu, Kitikan Thana-Udom, Linda M. Ercoli, Prabha Siddarth A Randomized Double-Blind Placebo-Controlled Trial of Combined Escitalopram and Memantine for Older Adults With Major Depression and Subjective Memory Complaints. American Journal of Geriatric Psychiatry. (2019). doi:10.1016/j.jagp.2019.08.011 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/52308
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A Randomized Double-Blind Placebo-Controlled Trial of Combined Escitalopram and Memantine for Older Adults With Major Depression and Subjective Memory Complaints
Abstract
© 2019 American Association for Geriatric Psychiatry Objective: Geriatric depression is difficult to treat and frequently accompanied by cognitive complaints that increase risk for dementia. New treatment strategies targeting both depression and cognition are urgently needed. Methods: We conducted a 6-month double-blind placebo-controlled trial to assess the efficacy and tolerability of escitalopram + memantine (ESC/MEM) compared to escitalopram + placebo (ESC/PBO) for improving mood and cognitive functioning in depressed older adults with subjective memory complaints (NCT01902004). Primary outcome was change in depression as assessed by the HAM-D post-treatment (at 6 months). Remission was defined as HAM-D ≤6; naturalistic follow-up continued until 12 months. Results: Of the 95 randomized participants, 62 completed the 6-month assessment. Dropout and tolerability did not differ between groups. Mean daily escitalopram dose was 11.1 mg (SD = 3.7; range: 5–20 mg). Mean daily memantine dose was 19.3 mg (SD = 2.6; range 10–20 mg). Remission rate within ESC/MEM was 45.8% and 47.9%, compared to 38.3% and 31.9% in ESC/PBO, at 3 and 6 months, respectively (χ2(1) = 2.0, p = 0.15). Both groups improved significantly on the HAM-D at 3, 6, and 12 months, with no observed between-group differences. ESC/MEM demonstrated greater improvement in delayed recall (F(2,82) = 4.3, p = 0.02) and executive functioning (F(2,82) = 5.1, p = 0.01) at 12 months compared to ESC/PBO. Conclusions: The combination of memantine with escitalopram was well tolerated and as effective as escitalopram and placebo in improving depression using HAM-D. Combination memantine and escitalopram was significantly more effective than escitalopram and placebo in improving cognitive outcomes at 12 months. Future reports will address the role of biomarkers of aging in treatment response.